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Objective: To explore serum caveolin-3 (Cav-3) levels in patients with atrial fibrillation
(AF) and to evaluate the role of Cav-3 as a biomarker for AF and incident heart failure (HF).
Methods: Three hundred and five patients were enrolled in the study and divided into
three groups: sinus rhythm (Group SR), paroxysmal AF (Group paAF), and persistent
AF (Group peAF). Serum Cav-3 concentrations were measured by enzyme-linked
immunosorbent assay at baseline. Clinical characteristics, and laboratory data were
collected during hospitalization, and a follow-up of 12-months was carried out.
Results: Serum Cav-3 concentrations were significantly decreased on the Group SR
and the highest concentrations of Cav-3 in patients were found on the Group peAF
(516.7± 274.0 vs. 609.3± 287.0 vs. 688.3± 264.6 ng/L, P < 0.05). Left atrial diameter
(LAD) in the Group peAF was significantly higher than in the Group paAF, and the Group
SR had significantly lower LAD than the Group paAF and Group peAF. The risks of
new-onset HF in the Group SR, Group paAF, andGroup peAFwere 8.1, 14.5, and 28.6%,
respectively. There was a significant difference between the Group peAF and the other
two groups. Serum Cav-3 concentrations were trisected in AF participants (lower tertile:
≤498, middle tertile: >498–703, upper tertile: ≥703). In further tertile studies, subjects
in the lower tertile of Cav-3 concentrations were more likely to become paroxysmal AF
and had much lower LAD (P < 0.05). And in the middle and upper tertiles, participants
with AF tended to suffer from HF compared to the lower group (P < 0.05).
Conclusion: We provide evidence that Cav-3 has a significant meaning in AF patients.
The levels of Cav-3 may be related to the LAD and new-onset HF.
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INTRODUCTION
Atrial fibrillation (AF) is themost common sustained cardiac arrhythmia, and it has been associated
with an increased risk of stroke, heart failure (HF), cognitive dysfunction, impaired quality of life,
as well as substantial health care costs, and eventually it contributes to an increased risk of cardiac
and total mortality (Camm et al., 2010, 2012; January et al., 2014). Furthermore, it has shown that
8.8 million adults over 55 years had AF in 2010 and this number will more than double to 17.9
million by 2060 in the European Union (Krijthe et al., 2013). Considering the increased risks of
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diseases and mortality, expensive costs and increasing number of
individuals associated with AF, there is a need for new biomarkers
to assess AF.
Caveolae are small flask-like membrane invaginations and
specialized microdomains in the sarcolemmal membrane of
cardiomyocytes (Williams and Lisanti, 2004). Caveolae contain a
variety of signaling proteins and cell surface receptors, including
upstream entities [e.g., G protein-coupled receptors (Cohen
et al., 2004; Ostrom and Insel, 2004), kinases (Prevostel et al.,
2000) and phosphatases (Nilsson et al., 2006)] and downstream
components (e.g., effector enzymes and ion channels; Vatta
et al., 2006), which participate in membrane trafficking, sorting,
transport, and signal transduction (Patel et al., 2008). And a
multitude of studies focused on caveolin-3 (Cav-3) knockout
(Woodman et al., 2002) and transgenic mice (Aravamudan et al.,
2003; Patel et al., 2008) have highlighted the potential role of Cav-
3 in cardiovascular pathophysiology. Cav-3 has been identified
as a muscle-specific form of the caveolin family and plays a
significant role in the pathophysiology of the heart (Williams and
Lisanti, 2004), such as, cardiac arrhythmias (Vatta et al., 2006;
Schilling et al., 2016), myocardial ischemia/reperfusion injury
(Zhao et al., 2013), cardiac hypertrophy (Patel et al., 2008), and
heart failure (Feiner et al., 2011).
Furthermore, recent evidence has suggested that caveolin-1
acting as an important anti-fibrotic signaling mediator plays a
crucial role in the fibrosis of AF (Yi et al., 2014). However, little
was known about the effects of Cav-3 on individuals with AF.
The purpose of this study attempts to investigate serum Cav-
3 levels in AF patients, to explore the associations of Cav-3
with AF and incident HF, to evaluate the correlation of Cav-3
with echocardiographic parameters (left atrial diameter, LAD), to
evaluate the role of Cav-3 as a biomarker for AF and incident HF.
We hypothesized that Cav-3 might provide novel insights into
the diagnosis and prognosis of AF.
MATERIALS AND METHODS
Study Population
Between January and June 2015, our study enrolled 305
consecutive patients into the prospective, single-center project.
According to standard clinical practice, all enrolled individuals
who underwent 12-lead electrocardiograms (ECGs) and/or
24-h Holter monitoring. According to the diagnose and
procedures of the Guidelines (Camm et al., 2010; January et al.,
2014), individuals selected into our study were those patients
diagnosed as AF. Patients were classified into 3 groups: those
with sinus rhythm (Group SR), those with paroxysmal AF
(Group paAF: self-terminating or with intervention within 7
days of onset), and those with persistent AF (Group peAF:
lasting >7 days, and including long-standing persistent AF:
continuous AF > 12 months in duration). Patient demographics,
clinical diagnoses, laboratory results, brain CT scan, and
echocardiogram examination were collected. Participants self-
reported smoking and drinking status. Diagnosed diabetes
mellitus (DM), hypertension and coronary artery disease (CAD)
were defined as a self-reported physician diagnosis or current
use of medications. Exclusion criteria were the following: cardiac
valvular disease, stroke, congestive HF or reduced left ventricular
ejection fraction (LVEF) <50%. Of the 356 subjects screened
for inclusion, 305 patients met the inclusion criteria, and 51
individuals met 1 of the exclusion criteria. This study protocol
was approved by the Institutional Review Board of the First
Affiliated Hospital of Wenzhou Medical University, and all
enrolled participants provided written informed consent.
Measurement of Cav-3 and Other
Exposure Variables
Blood samples were collected from the peripheral veins on
enrollment and anticoagulated with ethylenediaminetetraacetic
acid. After centrifugation at 3,000 rpm for 10 min at 4◦C, the
serum was separated and stored at −80◦C in aliquots until
analysis. Samples were thawed only once before measurement.
We measured Cav-3 in stored aliquots, using the Roche Cav-
3 reagent kit, a sandwich immunoassay, performed on a
Roche Elecsys 2010 Analyzer (Roche Diagnostics, Indianapolis,
Indiana). Serum lipid concentrations, serum glucose, C-reactive
protein (CRP), N-terminal probrain natriuretic peptide (NT pro-
BNP) were determined with standardized protocols.
Follow-Up
All subjects were contacted via telephone, an outpatient clinic
and hospitalizationwith follow-up every 3months. At last follow-
up, we collected the records of 12-lead ECGs and/or 24-h Holter
monitoring, and echocardiogram evaluation for all participants.
Major adverse events, including ischemic stroke, hospitalization,
AF recurrence, HF, all-cause death, were recorded. AF recurrence
was identified by symptoms with ECG documentation of an
AF lasting <30 s on a 12-lead ECG, event recording, or
Holter monitor recording. For those patients underwent catheter
ablation, AF that occurred was not counted as recurrences during
the first 2 months. HF was defined with the records based on
decreased LVEF (<50%) and the clinical symptoms and signs
(e.g., breathlessness, orthopnea, fatigue, ankle swelling, elevated
jugular venous pressure, pulmonary crackles, and S3 gallop).
Patients with NT-pro BNP values in between 100 and 400
pg/ml needed to be assessed clinically. These clinical signs and
symptoms almost have required diuretics, inotropic support or
vasodilator therapy.
Statistical Analysis
Normally distributed variables are expressed as mean± standard
deviation (SD) and compared using one-way analysis of variance.
We further divided AF participants into trisection based on
distribution of Cav-3. Two-sided P < 0.05 were considered
to indicate statistical significance (SPSS Statistics ver. 20.0,
IBM Corporation, Armonk, USA). Figures were made using
GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA).
RESULTS
Characteristics of the Study Population
The demographic, clinical characteristics, and laboratory findings
for all 305 patients enrolled in the present study are summed in
Table 1. Totally, 124 patients with SR (age, 62.8 ± 11.9 years;
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TABLE 1 | Baseline demographic and clinical characteristics of study participants.
Characteristics Group SR Group paAF Group peAF P-value
Participants, n (%) 124 (40.7) 76 (24.9) 105 (34.4)
DEMOGRAPHIC DATA
Age, years 62.8 ± 11.9 65.8 ± 10.8 66.7 ± 10.8 P < 0.05&
Female (%) 43 (34.7) 32 (42.1) 37 (35.2) NS
BMI, kg/m2 25.4 ± 4.6 24.0 ± 3.0 25.2 ± 3.4 P < 0.05#,*
Duration of AF, years – 2.6 ± 3.7 4.7 ± 5.2 P < 0.05*
MEDICAL HISTORY, n (%)
CAD, n (%) 43 (34.7) 20 (26.3) 27 (25.6) NS
Hypertension, n (%) 67 (54.0) 41 (53.9) 63 (60.0) NS
DM, n (%) 24 (19.4) 18 (23.7) 25 (23.8) NS
Smoking, n (%) 38 (30.6) 17 (22.4) 24 (22.6) NS
Alcoholism, n (%) 28 (22.6) 13 (17.1) 21 (20.0) NS
LABORATORY MEASUREMENTS
Caveolio-3, ng/L 516.7 ± 274.0 609.3 ± 287.0 688.3 ± 264.6 P < 0.05
NT pro-BNP, pg/ml 183.2 ± 380.5 195.9 ± 239.0 278.2 ± 234.1 NS
Ccr, ml/min 84.4 ± 29.0 78.2 ± 27.3 78.1 ± 27.4 NS
LDL-C, mmol/l 2.6 ± 1.0 2.7 ± 1.1 2.9 ± 1.7 NS
CRP, mg/L 6.2 ± 10.4 9.4 ± 20.5 10.4 ± 20.8 NS
Serum glucose, mmol/L 5.2 ± 1.4 6.1 ± 4.6 5.5 ± 1.7 NS
ECHOCARDIOGRAPHIC DATA
LAD, mm 40.8 ± 5.9 43.4 ± 5.6 49.0 ± 6.3 P < 0.05
LVEDD, mm 50.7 ± 7.5 49.8 ± 6.3 50.7 ± 6.5 NS
LVEF, (%) 62.3 ± 12.1 62.2 ± 8.8 60.9 ± 10.5 NS
CA, n (%) 0 30 (39.5) 37 (35.2) NS*
BMI, Body mass index; CAD, coronary artery disease; DM, Diabetes mellitus; Ccr, Creatinine clearance rate; LDL-C, low density lipoprotein-cholesterol; CRP, C-reactive protein; LAD,
left atrial diameter; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; CA, catheter ablation.
#P < 0.05, P-value between the Group SR and the Group paAF.
&P < 0.05, P-value between the Group SR and the Group peAF.
*P < 0.05, P-value between the Group paAF and the Group peAF.
P < 0.05, overall.
NS, no significance; NS*, no significance between the Group paAF and the Group peAF.
sex, 34.7% female), 76 with paroxysmal AF (age, 65.8 ± 10.8
years; sex, 42.1% female), and 105 with persistent AF (age, 66.7
± 10.8 years; sex, 35.2% female) were included. Participants in
the Group peAF were older than those in the Group SR (P
< 0.05). And the Group paAF had a much lower BMI than
the other two groups (P < 0.05). Data from medical history
(CAD, hypertension, DM, etc) and clinical parameters (NT-pro
BNP, CRP, Creatinine clearance rate, etc) showed no significant
differences among the three groups. Among the three groups,
serum Cav-3 concentrations were significantly decreased on the
Group SR and the highest concentrations of Cav-3 in patients
were found on the Group peAF (516.7 ± 274.0 vs. 609.3 ±
287.0 vs. 688.3 ± 264.6 ng/L, P < 0.05) (Figure 1A). Similarly,
regarding echocardiographic analysis, there were significant
differences among the three groups in the LAD (Figure 1B). LAD
in the Group peAF were larger than those in the Group paAF, and
the Group SR demonstrated the lowest LAD among three groups
(Figure 1B).
Furthermore, serum Cav-3 concentrations measured in
AF participants were classified into trisection (lower tertile:
≤498, middle tertile: >498–703, upper tertile: ≥703) (Table 2).
FIGURE 1 | Differences of Caveolio-3 concentrations (A) and left atrial
diameter (B) among three groups.
Participants with lower serum Cav-3 concentrations were more
likely to become paroxysmal AF (P < 0.05) (Figure 2A). As
presented in Table 2, the numbers of persistent AF patients
were 39 and 40, respectively. In the middle and upper tertiles,
the Group peAF had higher levels of Cav-3 than the Group
paAF. In further study to evaluate the relationship between Cav-
3 concentrations and echocardiographic parameters, subjects in
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TABLE 2 | Demographics and Clinical Characteristics at Baseline by tertile of circulating Cav-3 concentrations in AF subjects.
Caveolio-3 Level, ng/L P-value
≤498 >498–703 ≥703
Participants, n (%) 60 60 61
paAF, n (%) 34 (56.7) 21 (35.0) 21 (34.4) P < 0.05#,&
peAF, n (%) 26 (43.3) 39 (65.0) 40 (65.6) P < 0.05#,&
DEMOGRAPHIC DATA
Age, years 64.6 ± 10.2 67.3 ± 11.0 67.0 ± 11.1 NS
Female (%) 24 (40.0) 19 (31.7) 26 (43.3) NS
BMI, kg/m2 24.7 ± 3.5 24.4 ± 3.0 25.0 ± 3.4 NS
Duration of AF, years 3.4 ± 4.9 4.3 ± 5.0 3.8 ± 4.2 NS
MEDICAL HISTORY, N (%)
CAD, n (%) 14 (23.3) 16 (26.7) 17 (27.9) NS
Hypertension, n (%) 30 (50.0) 35 (58.3) 39 (63.9) NS
DM, n (%) 14 (23.3) 14 (23.3) 15 (24.6) NS
Smoking, n (%) 13 (21.7) 17 (28.3) 11 (18.0) NS
Alcoholism, n (%) 10 (16.7) 14 (23.3) 10 (16.4) NS
MEDICAL HISTORY, N (%)
NT pro-BNP, pg/ml 218.0 ± 228.7 256.9 ± 209.7 255.9 ± 274.6 NS
Ccr, ml/min 82.5 ± 26.7 75.6 ± 30.3 76.4 ± 24.5 NS
LDL-C, mmol/l 3.0 ± 2.2 2.6 ± 0.8 2.8 ± 1.0 NS
CRP, mg/L 7.5 ± 16.9 8.5 ± 18.5 13.6 ± 25.0 NS
Serum glucose, mmol/L 5.3 ± 1.1 6.1 ± 4.9 5.7 ± 2.4 NS
ECHOCARDIOGRAPHIC DATA
LAD, mm 44.4 ± 5.9 47.8 ± 6.4 47.2 ± 7.2 P < 0.05#,&
LVEDD, mm 50.1 ± 6.0 50.2 ± 6.8 50.9 ± 6.3 NS
LVEF, (%) 61.9 ± 9.0 61.2 ± 10.0 61.4 ± 10.2 NS
CA, n (%) 27 (45.0) 19 (31.7) 21 (34.4) NS
BMI, Body mass index; CAD, coronary artery disease; DM, Diabetes mellitus; Ccr, Creatinine clearance rate; LDL-C, low density lipoprotein-cholesterol; CRP, C-reactive protein; LAD,
left atrial diameter; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; CA, catheter ablation; NS, no significance.
#P < 0.05, P-value between the Group SR and the Group paAF.
&P < 0.05, P-value between the Group SR and the Group peAF.
FIGURE 2 | Differences in number of participants (A) and left atrial diameter (B) in the Group paAF and the Group peAF by tertile of circulating Cav-3
concentrations.
the lower tertile of Cav-3 had lower LAD, compared to the
other two groups (P < 0.05) (Figure 2B). And the middle and
upper tertiles demonstrated no statistical differences between the
Group paAF and the Group peAF. There were no significant
differences of LAD between the middle tertile and upper tertile.
In tertile analysis, no significant differences were observed
between serum Cav-3 in medical history (CAD, hypertension,
DM, etc), clinical parameters (NT-pro BNP, CRP, Creatinine
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clearance rate, etc) and echocardiographic measurements (left
ventricular end-diastolic dimension and LVEF) among the three
groups.
During follow-up period of 12 months, 4 patients died, 4
suffered from stroke, 11 were with AF recurrence, 34 were
readmitted, and 51 developed HF. There had no significant
differences about all-cause death, stroke and hospitalization
among the three groups, and no significant differences about
AF recurrence between the Group paAF and the Group peAF.
The risks of new-onset HF in the Group SR, Group paAF, and
Group peAF were 8.1, 14.5, and 28.6%, respectively. Patients
in the Group peAF had a much higher risk to develop new-
onset HF than other two groups, while no differences were
shown in the Group SR and the Group paAF (Figure 3A). With
further tertile analysis of Cav-3, the lower tertile demonstrated
the lowest risk of new-onset HF among the three groups and
had a significant difference compared with the middle and upper
tertiles (Figure 3B). Major adverse events were displayed in
Tables 3, 4.
DISCUSSION
There is a growing body of data within the literature that
implicate Cav3 as a causative agent of a wide range of
cardiovascular pathophysiologies (Vatta et al., 2006; Patel et al.,
2008; Tsutsumi et al., 2008; Feiner et al., 2011; Zhao et al., 2013;
Schilling et al., 2016). Of the above studies, the function of Cav-3
has been represented in animal models. There has lacked clinical
data to confirm the effect of Cav-3 on heart disease, even less on
AF. The major findings generated from our study are as follows:
high Cav-3 had a significant relationship with AF participants
compared with patients in SR. In addition, Cav-3 concentrations
were much higher in the Group peAF than the Group paAF. It
showed that concentrations of Cav-3 might be associated with
the frequency and duration of AF. And moreover, our study
demonstrated that levels of Cav-3 had a close relationship with
LAD, a common and vital risk factor of AF. Regarding incident
HF in AF subjects, Cav-3 concentrations had a certain association
with the occurrence of HF.
Studies spanning more than several decades still reach no
consensus on certain mechanisms of AF (Camm et al., 2010;
January et al., 2014). It currently tends to acceptable that
pathophysiological changes (Kistler et al., 2004; Schotten et al.,
2011) and electrophysiological disorders (Haïssaguerre et al.,
1998; Calkins et al., 2012) trigger for the onset of AF. Abnormal
intracellular potassium and calcium handling, as well as ion
channels, may play a role in AF. Similarly, atrial structural
remodeling facilitates the initiation and perpetuation of AF.
Perturbation of atrial contractile function also occurs within days
of AF. Either pathophysiological changes or electrophysiological
disorders may initiate the onset of AF, but both of them
coexist in perpetuation of AF (Schotten et al., 2011). To our
TABLE 3 | Major adverse events of study participants.
Group SR Group paAF Group peAF P-value
N = 124 N = 76 N = 105
All-cause death, n (%) 0 2 (2.6) 2 (1.9) NS
Hospitalization, n (%) 10 (8.1) 14 (18.4) 20 (19.0) NS
Stroke, n (%) 0 1 (1.3) 3 (2.9) NS
AF recurrence, n (%) 0 6 (7.9) 5 (4.8) NS*
HF, n (%) 10 (8.1) 11 (14.5) 30 (28.6) P < 0.05#,*
HF, heart failure; AF, atrial fibrillation; NS, no significance; NS*, no significance between
the Group paAF and the Group peAF.
#P < 0.05, P-value between the Group SR and the Group paAF.
*P < 0.05, P-value between the Group paAF and the Group peAF.
P < 0.05, overall.
TABLE 4 | Major adverse events of AF participants by tertile of circulating
Cav-3 concentrations in AF subjects.
Caveolio-3 Level, ng/L P-value
≤498 (60) >498–703 (60) ≥703 (61)
All-cause death, n (%) 1 (1.7) 0 3 (4.9) NS
Hospitalization, n (%) 10 (16.7) 16 (26.7) 8 (13.1) NS
Stroke, n (%) 0 3 (5.0) 1 (1.6) NS
AF recurrence, n (%) 4 (14.8) 4 (21.1) 3 (14.3) NS
HF, n (%) 5 (8.3) 17 (28.3) 19 (31.1) P < 0.05#,&
HF, heart failure; AF, atrial fibrillation; NS, no significance.
#P < 0.05, P-value between the Group SR and the Group paAF.
&P < 0.05, P-value between the Group SR and the Group peAF.
P < 0.05, overall.
FIGURE 3 | Differences in number of incident heart failure in the Group SR, the Group paAF, and the Group peAF (A), and in the tertile of Cav-3 (B).
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knowledge, Cav-3 takes a significant part in arrhythmias (Vatta
et al., 2006; Schilling et al., 2016) and cardiac hypertrophy (Patel
et al., 2008). Cav-3 plays a critical role in organizing signaling
molecules (Cohen et al., 2004; Ostrom and Insel, 2004) and
ion channels (Patel et al., 2008) involved in cardiac conduction
and hypertrophy. Previous work demonstrates that Cav-3
overexpression in cardiomyocytes is essential for promoting
the protective signaling in pathological cardiac hypertrophy
(Markandeya et al., 2015). On the contrary, loss of Cav-3
expression is prone to induce a molecular program leading to
cardiomyocytes hypertrophy and cardiomyopathy (Woodman
et al., 2002). Considering that the crucial effect of Cav-3 on
the heart, we harbor the idea that Cav-3 also has a close
relationship with AF. Those findings observed from animal
models are consistent with our clinical study. Similar findings
are demonstrated in our study that Cav-3 concentrations are
reduced in the patients with SR compared with those in AF
patients. To the further extent, the Group paAF has higher levels
of Cav-3 than the Group peAF. In tertile analysis, subjects in the
Group paAF tend to have the lower levels of Cav-3. Similarly,
the first tertile has lower LAD and lower occurrence of HF
than the other two groups. Accordingly, we could speculate
that Cav-3 has a certain relationship with the paroxysmal AF,
LAD, and incident HF. However, when Cav-3 concentrations
are beyond some specific value, we find no direct interaction
between Cav-3 and AF, as well as LAD, occurrence of HF. Our
study was limited by a small study population and short follow-
ups. Further studies with subsequent follow-up are favored.
Patients were recruited from a single university hospital. And
there was missing Cav-3 sample collected at the last follow-
ups. The pathophysiological role of Cav-3 in AF needs further
studies.
The present study shows that serum Cav-3 levels are
significantly elevated and have a significant meaning in AF
patients. The levels of Cav-3 may be related to the LAD and
new-onset HF.
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